These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 31604755)

  • 21. Evaluating how has care been affected by the Ontario COVID-19 Opioid Agonist Treatment Guidance: Patients' and prescribers' experiences with changes in unsupervised dosing.
    Corace K; Suschinsky K; Wyman J; Leece P; Cragg S; Konefal S; Pana P; Barrass S; Porath A; Hutton B
    Int J Drug Policy; 2022 Apr; 102():103573. PubMed ID: 35123246
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Association of Opioid Agonist Treatment With All-Cause Mortality and Specific Causes of Death Among People With Opioid Dependence: A Systematic Review and Meta-analysis.
    Santo T; Clark B; Hickman M; Grebely J; Campbell G; Sordo L; Chen A; Tran LT; Bharat C; Padmanathan P; Cousins G; Dupouy J; Kelty E; Muga R; Nosyk B; Min J; Pavarin R; Farrell M; Degenhardt L
    JAMA Psychiatry; 2021 Sep; 78(9):979-993. PubMed ID: 34076676
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Initiation of opioid agonist therapy after hospital visits for opioid poisonings in Ontario.
    Hu T; McCormack D; Juurlink DN; Campbell TJ; Bayoumi AM; Leece P; Kent JT; Gomes T
    CMAJ; 2023 Dec; 195(49):E1709-E1717. PubMed ID: 38110219
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Trends in engagement in the cascade of care for opioid use disorder, Vancouver, Canada, 2006-2016.
    Socías ME; Wood E; Kerr T; Nolan S; Hayashi K; Nosova E; Montaner J; Milloy MJ
    Drug Alcohol Depend; 2018 Aug; 189():90-95. PubMed ID: 29894910
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Twelve-Month Retention in Opioid Agonist Treatment for Opioid Use Disorder Among Patients With and Without HIV.
    Wyse JJ; McGinnis KA; Edelman EJ; Gordon AJ; Manhapra A; Fiellin DA; Moore BA; Korthuis PT; Kennedy AJ; Oldfield BJ; Gaither JR; Gordon KS; Skanderson M; Barry DT; Bryant K; Crystal S; Justice AC; Kraemer KL
    AIDS Behav; 2022 Mar; 26(3):975-985. PubMed ID: 34495424
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Inequities in access to primary care among opioid recipients in Ontario, Canada: A population-based cohort study.
    Gomes T; Campbell TJ; Martins D; Paterson JM; Robertson L; Juurlink DN; Mamdani M; Glazier RH
    PLoS Med; 2021 Jun; 18(6):e1003631. PubMed ID: 34061846
    [TBL] [Abstract][Full Text] [Related]  

  • 27. State criminal justice policy context and opioid agonist treatment delivery among opioid treatment admissions, 2015.
    Mantha S; Mauro PM; Mauro CM; Martins SS
    Drug Alcohol Depend; 2020 Jan; 206():107654. PubMed ID: 31735533
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Uptake of slow-release oral morphine as opioid agonist treatment among hospitalised patients with opioid use disorder.
    Brothers TD; Fraser J; MacAdam E; Morgan B; Webster D
    Drug Alcohol Rev; 2022 Feb; 41(2):430-434. PubMed ID: 34347327
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A qualitative analysis of barriers to opioid agonist treatment for racial/ethnic minoritized populations.
    Husain JM; Cromartie D; Fitzelle-Jones E; Brochier A; Borba CPC; Montalvo C
    J Subst Abuse Treat; 2023 Jan; 144():108918. PubMed ID: 36403456
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Medicaid Coverage of Methadone Maintenance and the Use of Opioid Agonist Therapy Among Pregnant Women in Specialty Treatment.
    Bachhuber MA; Mehta PK; Faherty LJ; Saloner B
    Med Care; 2017 Dec; 55(12):985-990. PubMed ID: 29135769
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Canadian Addiction Treatment Centre (CATC) opioid agonist treatment cohort in Ontario, Canada.
    Morin KA; Tatangelo M; Marsh D
    BMJ Open; 2024 Feb; 14(2):e080790. PubMed ID: 38401902
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Trends in Rates of Opioid Agonist Treatment and Opioid-Related Deaths for Youths in Ontario, Canada, 2013-2021.
    Rosic T; Kolla G; Leece P; Kitchen S; Gomes T
    JAMA Netw Open; 2023 Jul; 6(7):e2321947. PubMed ID: 37410463
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Incidence and factors associated with discontinuation of opioid agonist therapy among people who inject drugs in Australia.
    Geddes L; Iversen J; Wand H; Maher L
    Addiction; 2021 Mar; 116(3):525-535. PubMed ID: 32557931
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Determinants of interest in extended-released buprenorphine: A survey among 366 French patients treated with buprenorphine or methadone.
    Rolland B; Trojak B; Nourredine M; Bachellier J; Chappuy M; Bendimerad P; Kosim M; Hjelmström P; Meroueh F; Nubukpo P; Brousse G
    Drug Alcohol Depend; 2021 Mar; 220():108492. PubMed ID: 33482572
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The Affordable Care Act and Opioid Agonist Therapy for Opioid Use Disorder.
    Mojtabai R; Mauro C; Wall MM; Barry CL; Olfson M
    Psychiatr Serv; 2019 Jul; 70(7):617-620. PubMed ID: 31035894
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Global opioid agonist treatment: a review of clinical practices by country.
    Jin H; Marshall BDL; Degenhardt L; Strang J; Hickman M; Fiellin DA; Ali R; Bruneau J; Larney S
    Addiction; 2020 Dec; 115(12):2243-2254. PubMed ID: 32289189
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The impact of the 2014 military conflict in the east of Ukraine and the Autonomous Republic of the Crimea among patients receiving opioid agonist therapies.
    Meteliuk A; Sazonova Y; Goldmann E; Xu S; Liutyi V; Liakh T; Spirina T; Lekholetova M; Islam Z; Ompad DC
    J Subst Use Addict Treat; 2024 May; 160():209312. PubMed ID: 38336264
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Predictors of timely opioid agonist treatment initiation among veterans with and without HIV.
    Wyse JJ; Robbins JL; McGinnis KA; Edelman EJ; Gordon AJ; Manhapra A; Fiellin DA; Moore BA; Korthuis PT; Gaither JR; Gordon K; Skanderson M; Barry DT; Crystal S; Justice A; Kraemer KL
    Drug Alcohol Depend; 2019 May; 198():70-75. PubMed ID: 30878769
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Interim opioid agonist treatment for opioid addiction: a systematic review.
    Samsó Jofra L; Puig T; Solà I; Trujols J
    Harm Reduct J; 2022 Jan; 19(1):7. PubMed ID: 35090475
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Impact of the COVID-19 pandemic on the prevalence of opioid agonist therapy discontinuation in Ontario, Canada: A population-based time series analysis.
    Garg R; Kitchen SA; Men S; Campbell TJ; Bozinoff N; Tadrous M; Antoniou T; Wyman J; Werb D; Munro C; Gomes T
    Drug Alcohol Depend; 2022 Jul; 236():109459. PubMed ID: 35489179
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.